Company news

COSCIENS Biopharma Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD to be Presented at Upcoming GRS and IGF Society Congress

October 10, 2012

Aeterna Zentaris Announces Share Consolidation to Regain NASDAQ Compliance

October 3, 2012

Aeterna Zentaris Presented Poster on Oral Prostate Cancer Vaccine, AEZS-120, at International Urology Conference in Japan

October 2, 2012

Aeterna Zentaris Provides Update on NDA Filing for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency

September 26, 2012

Aeterna Zentaris Granted Patent by European Patent Office for AEZS-130 in Growth Hormone Deficiency Diagnosis

September 25, 2012

Aeterna Zentaris to Present Poster on Oral Prostate Cancer Vaccine Candidate, AEZS-120, at Upcoming International Urology Conference in Japan

September 20, 2012

Aeterna Zentaris to Present at Rodman & Renshaw 14th Annual Global Investment Conference in New York

September 5, 2012

Aeterna Zentaris to Present at Stifel Nicolaus Healthcare Conference in Boston

August 29, 2012

Aeterna Zentaris Announces First Patient Recruited for Phase 2A Trial in Cancer Cachexia with AEZS-130

August 28, 2012

Aeterna Zentaris Reports Second Quarter 2012 Financial and Operating Results

August 14, 2012

Aeterna Zentaris to Present Preclinical Data for PI3K/Erk 1/2 Inhibitor, AEZS-136, at ACS National Meeting

August 13, 2012

Aeterna Zentaris to Announce Second Quarter 2012 Financial and Operating Results on August 14, 2012

August 8, 2012

Aeterna Zentaris Granted Patent in the U.S. for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency

August 7, 2012

Aeterna Zentaris: Preclinical Data for AEZS-108 in Bladder Cancer Published Online in Oncotarget

July 26, 2012

Aeterna Zentaris Requests Fast Track Designation from the FDA for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency

July 24, 2012

Aeterna Zentaris to Present at 7th Annual JMP Securities Healthcare Conference in New York

July 5, 2012

Aeterna Zentaris: Partner Yakult Initiates Phase 1 Trial in Multiple Myeloma with Perifosine in Japan

June 28, 2012

Aeterna Zentaris: Final Phase 3 Results for AEZS-130 in Adult Growth Hormone Deficiency Presented at ENDO Meeting

June 26, 2012

Aeterna Zentaris: Phase 1 Results Show Perifosine's Activity Against Neuroblastoma

June 21, 2012

Aeterna Zentaris Learns of Class Action Lawsuits Filed and Denies Allegations

June 19, 2012

Aeterna Zentaris: Phase 2 Data for Perifosine as Monotherapy for Renal Cell Carcinoma Published in June Issue of Cancer

June 18, 2012

Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD to be Presented at Upcoming ENDO Meeting

June 14, 2012

Aeterna Zentaris: Poster on Phase 1 Results for Perifosine in Neuroblastoma to be Presented at Upcoming Neuroblastoma Research Conference in Toronto

June 13, 2012

Aeterna Zentaris: Phase 1 Data for Perifosine in Multiple Myeloma Published in the British Journal of Haematology

June 5, 2012

Aeterna Zentaris: Phase 3 Data for Perifosine in Colorectal Cancer Presented at ASCO Meeting

June 4, 2012

Aeterna Zentaris: Article on Perifosine as Potential Novel Approach to the Treatment of Mesothelioma Published in Plos One

May 31, 2012

Aeterna Zentaris Reports First Quarter 2012 Financial and Operating Results

May 9, 2012

Aeterna Zentaris Regains North American Rights for Perifosine from Keryx

May 7, 2012

Aeterna Zentaris to Present at 11th Annual JMP Securities Research Conference in San Francisco

May 3, 2012

Aeterna Zentaris to Announce First Quarter 2012 Financial and Operating Results and Hold Annual Shareholders Meeting on May 9, 2012

May 1, 2012

Aeterna Zentaris Presents Preclinical Data for Its Anti-Cancer PI3K/ Erk 1/2 Inhibitor, AEZS-136, at AACR Meeting

April 3, 2012

Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer

April 2, 2012

Aeterna Zentaris to Present at Needham Healthcare Conference in New York

March 29, 2012

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2011 Financial and Operating Results

March 27, 2012

Aeterna Zentaris to Present Preclinical Data for Anticancer Compounds Perifosine and AEZS-136 at Upcoming AACR Meeting

March 26, 2012

Aeterna Zentaris to Announce Fourth Quarter and Full Year 2011 Financial and Operating Results on March 27, 2012

March 20, 2012

Michael E. DeBakey VA Medical Center Initiates Phase 2A Trial in Cancer Cachexia with Aeterna Zentaris' Ghrelin Agonist, AEZS-130

March 8, 2012

Aeterna Zentaris to Present at Cowen and Company 32nd Annual Health Care Conference in Boston

February 29, 2012

Aeterna Zentaris to Present at BIO CEO Investor and RBC Capital Markets Global Healthcare Conferences in New York

February 7, 2012

Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting

February 3, 2012

Aeterna Zentaris: Updated Interim Phase 1 Trial Results for AEZS-108 in Prostate Cancer To Be Presented at Upcoming ASCO GCS Meeting in San Francisco

January 26, 2012

Aeterna Zentaris Announces Collaboration with Ventana Medical Systems, Inc. to Develop Companion Diagnostic in Cancer for AEZS-108

January 5, 2012

Aeterna Zentaris Partner, Yakult Honsha, Initiates Phase 1/2 Trial with Perifosine in Colorectal Cancer in Japan

January 3, 2012

Aeterna Zentaris: Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting

December 13, 2011

Aeterna Zentaris: Encouraging Preclinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting

December 12, 2011

Aeterna Zentaris Presents Positive Preclinical Data in Breast Cancer on AEZS-131, a Highly Selective Erk 1/2 Inhibitor, at San Antonio Breast Cancer Symposium

December 9, 2011

Aeterna Zentaris: Presentations on Perifosine Scheduled at Upcoming ASH Meeting in San Diego, California

December 5, 2011

Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia

November 28, 2011

Aeterna Zentaris and Hikma Pharmaceuticals Sign a Commercialization and Licensing Agreement for Lead Oncology Compound, Perifosine, for Middle East and North Africa (MENA) Region

November 23, 2011

Aeterna Zentaris to Present at Upcoming Piper Jaffray and Oppenheimer Healthcare Conferences in New York

November 22, 2011

← Newer news releases · Older news releases →

Decks

The 5 newest of 7 decks. Every deck is listed under its year.